• Je něco špatně v tomto záznamu ?

Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder

H. Zhang, A. Iranzo, B. Högl, I. Arnulf, L. Ferini-Strambi, R. Manni, T. Miyamoto, WH. Oertel, Y. Dauvilliers, YE. Ju, M. Puligheddu, K. Sonka, A. Pelletier, JY. Montplaisir, A. Stefani, A. Ibrahim, B. Frauscher, S. Leu-Semenescu, M. Zucconi, M....

. 2022 ; 91 (3) : 404-416. [pub] 20220124

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010813

Grantová podpora
CIHR - Canada

OBJECTIVE: This study was undertaken to follow up predictive factors for α-synuclein-related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). METHODS: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. RESULTS: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21-0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. INTERPRETATION: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404-416.

C Mondino National Neurological Institute Pavia Italy

Center for Advanced Studies in Sleep Medicine Montreal Sacred Heart Hospital Montreal Quebec Canada

Department of Neurology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology Dokkyo Medical University Saitama Medical Center Saitama Japan

Department of Neurology Dokkyo Medical University School of Medicine Tochigi Japan

Department of Neurology Gui de Chauliac Hospital Montpellier National Institute of Health and Medical Research U1061 Montpellier France

Department of Neurology Innsbruck Medical University Innsbruck Austria

Department of Neurology McGill University Montreal General Hospital Montreal Quebec Canada

Department of Neurology Philipps University Marburg Germany

Department of Neurology University of Auvergne Clermont Ferrand France

Department of Neurology Washington University School of Medicine St Louis MO USA

Department of Neurology Xuanwu Hospital Capital Medical University Beijing China

Department of Psychiatry University of Montreal Montreal Quebec Canada

Neurology Service Hospital Clinic of Barcelona August Pi i Sunyer Biomedical Research Institute Center for Biomedical Research on Neurodegenerative Diseases Barcelona Spain

Paris Brain Institute and Sleep Disorder Unit Pitié Salpêtrière Hospital Public Hospital Network of Paris Sorbonne University Paris France

Sleep Center Department of Cardiovascular and Neurological Sciences University of Cagliari Cagliari Italy

Sleep Disorders Center Vita Salute San Raffaele University Milan Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010813
003      
CZ-PrNML
005      
20220506125802.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ana.26298 $2 doi
035    __
$a (PubMed)34981563
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Zhang, Hui $u Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing, China $u Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada $1 https://orcid.org/0000000185264440
245    10
$a Risk Factors for Phenoconversion in Rapid Eye Movement Sleep Behavior Disorder / $c H. Zhang, A. Iranzo, B. Högl, I. Arnulf, L. Ferini-Strambi, R. Manni, T. Miyamoto, WH. Oertel, Y. Dauvilliers, YE. Ju, M. Puligheddu, K. Sonka, A. Pelletier, JY. Montplaisir, A. Stefani, A. Ibrahim, B. Frauscher, S. Leu-Semenescu, M. Zucconi, M. Terzaghi, M. Miyamoto, A. Janzen, M. Figorilli, ML. Fantini, RB. Postuma
520    9_
$a OBJECTIVE: This study was undertaken to follow up predictive factors for α-synuclein-related neurodegenerative diseases in a multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD). METHODS: Patients with iRBD from 12 centers underwent a detailed assessment for potential environmental and lifestyle risk factors via a standardized questionnaire at baseline. Patients were then prospectively followed and received assessments for parkinsonism or dementia during follow-up. The cumulative incidence of parkinsonism or dementia was estimated with competing risk analysis. Cox regression analyses were used to evaluate the predictive value of environmental/lifestyle factors over a follow-up period of 11 years, adjusting for age, sex, and center. RESULTS: Of 319 patients who were free of parkinsonism or dementia, 281 provided follow-up information. After a mean follow-up of 5.8 years, 130 (46.3%) patients developed neurodegenerative disease. The overall phenoconversion rate was 24.2% after 3 years, 44.8% after 6 years, and 67.5% after 10 years. Patients with older age (adjusted hazard ratio [aHR] = 1.05) and nitrate derivative use (aHR = 2.18) were more likely to phenoconvert, whereas prior pesticide exposure (aHR = 0.21-0.64), rural living (aHR = 0.53), lipid-lowering medication use (aHR = 0.59), and respiratory medication use (aHR = 0.36) were associated with lower phenoconversion risk. Risk factors for those converting to primary dementia and parkinsonism were generally similar, with dementia-first converters having lower coffee intake and beta-blocker intake, and higher occurrence of family history of dementia. INTERPRETATION: Our findings elucidate the predictive values of environmental factors and comorbid conditions in identifying RBD patients at higher risk of phenoconversion. ANN NEUROL 2022;91:404-416.
650    _2
$a senioři $7 D000368
650    _2
$a demence $x epidemiologie $x etiologie $7 D003704
650    _2
$a progrese nemoci $7 D018450
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a životní styl $7 D008019
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neurodegenerativní nemoci $x epidemiologie $x etiologie $7 D019636
650    _2
$a porucha chování v REM spánku $x komplikace $7 D020187
650    _2
$a rizikové faktory $7 D012307
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Iranzo, Alex $u Neurology Service, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Center for Biomedical Research on Neurodegenerative Diseases, Barcelona, Spain
700    1_
$a Högl, Birgit $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Arnulf, Isabelle $u Paris Brain Institute and Sleep Disorder Unit, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Sorbonne University, Paris, France
700    1_
$a Ferini-Strambi, Luigi $u Sleep Disorders Center, Vita-Salute San Raffaele University, Milan, Italy $1 https://orcid.org/0000000328675424
700    1_
$a Manni, Raffaele $u C. Mondino National Neurological Institute, Pavia, Italy
700    1_
$a Miyamoto, Tomoyuki $u Department of Neurology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan $1 https://orcid.org/0000000265358260
700    1_
$a Oertel, Wolfgang H $u Department of Neurology, Philipps University, Marburg, Germany
700    1_
$a Dauvilliers, Yves $u Department of Neurology, Gui de Chauliac Hospital, Montpellier, National Institute of Health and Medical Research U1061, Montpellier, France $1 https://orcid.org/0000000306836506
700    1_
$a Ju, Yo-Ei $u Department of Neurology, Washington University School of Medicine, St Louis, MO, USA $1 https://orcid.org/0000000193977475
700    1_
$a Puligheddu, Monica $u Sleep Center, Department of Cardiovascular and Neurological Sciences, University of Cagliari, Cagliari, Italy
700    1_
$a Sonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Pelletier, Amélie $u Center for Advanced Studies in Sleep Medicine, Montreal Sacred Heart Hospital, Montreal, Quebec, Canada
700    1_
$a Montplaisir, Jacques Y $u Center for Advanced Studies in Sleep Medicine, Montreal Sacred Heart Hospital, Montreal, Quebec, Canada $u Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada
700    1_
$a Stefani, Ambra $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Ibrahim, Abubaker $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
700    1_
$a Frauscher, Birgit $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria $1 https://orcid.org/0000000160641529
700    1_
$a Leu-Semenescu, Smaranda $u Paris Brain Institute and Sleep Disorder Unit, Pitié-Salpêtrière Hospital, Public Hospital Network of Paris, Sorbonne University, Paris, France
700    1_
$a Zucconi, Marco $u Sleep Disorders Center, Vita-Salute San Raffaele University, Milan, Italy
700    1_
$a Terzaghi, Michele $u C. Mondino National Neurological Institute, Pavia, Italy $1 https://orcid.org/0000000196922218
700    1_
$a Miyamoto, Masayuki $u Department of Neurology, Dokkyo Medical University School of Medicine, Tochigi, Japan
700    1_
$a Janzen, Annette $u Department of Neurology, Philipps University, Marburg, Germany $1 https://orcid.org/0000000189075831
700    1_
$a Figorilli, Michela $u Sleep Center, Department of Cardiovascular and Neurological Sciences, University of Cagliari, Cagliari, Italy
700    1_
$a Fantini, Maria L $u Sleep Center, Department of Cardiovascular and Neurological Sciences, University of Cagliari, Cagliari, Italy $u Department of Neurology, University of Auvergne, Clermont-Ferrand, France
700    1_
$a Postuma, Ronald B $u Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada $u Center for Advanced Studies in Sleep Medicine, Montreal Sacred Heart Hospital, Montreal, Quebec, Canada $1 https://orcid.org/0000000264684734
773    0_
$w MED00000428 $t Annals of neurology $x 1531-8249 $g Roč. 91, č. 3 (2022), s. 404-416
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34981563 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125755 $b ABA008
999    __
$a ok $b bmc $g 1788772 $s 1162011
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 91 $c 3 $d 404-416 $e 20220124 $i 1531-8249 $m Annals of neurology $n Ann Neurol $x MED00000428
GRA    __
$p CIHR $2 Canada
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace